• Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it completed enrollment in a pivotal study of Captisol-enabled propylene glycol-free high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.